A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 1 Withdrawn Teva Branded Pharmaceutical Products R&D, Inc.

Non-randomizedSequentialOpen-labelOther

Summary

The purpose of this study is to determine the safety, tolerability, and recommended phase 2 dose (RP2D) of TAK-573 when used with dexamethasone and in combination with bortezomib, pomalidomide, or cyclophosphamide, in participants with RRMM.

Timeline

Start: 2020-06-24
Primary completion: 2023-11-10
Completion: 2023-11-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	1.3 mg/m2	Subcutaneous
Subject	Cyclophosphamide	Other / unclassified	300 mg/m2	Oral
Subject	Modakafusp alfa	Protein / enzyme biologic	0.05 mg/kg	Intravenous
Subject	Modakafusp alfa	Protein / enzyme biologic	0.1 mg/kg	Intravenous
Subject	Modakafusp alfa	Protein / enzyme biologic	0.75 mg/kg	Intravenous
Subject	Modakafusp alfa	Protein / enzyme biologic	1.5 mg/kg	Intravenous
Subject	Pomalidomide	Other / unclassified	4 mg	Oral
Background	Dexamethasone	Small molecule	20 mg	Oral
Background	Dexamethasone	Small molecule	40 mg	Oral

A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Summary

Timeline

Drugs

Indications